U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Recurrent Extensive Stage Lung Small Cell Carcinoma

MedGen UID:
1633456
•Concept ID:
C4683498
•
Neoplastic Process
Synonym: Recurrent Extensive Stage Small Cell Lung Carcinoma

Definition

Extensive stage small cell lung carcinoma that has reemerged after a period of remission. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRecurrent Extensive Stage Lung Small Cell Carcinoma

Professional guidelines

PubMed

Emerging Strategies for the Treatment of Small Cell Lung Cancer: A Review.
Petty WJ, Paz-Ares L
JAMA Oncol 2023 Mar 1;9(3):419-429. doi: 10.1001/jamaoncol.2022.5631. PMID: 36520421
Extensive-Stage Small-Cell Lung Cancer: First-Line and Second-Line Treatment Options.
Zugazagoitia J, Paz-Ares L
J Clin Oncol 2022 Feb 20;40(6):671-680. Epub 2022 Jan 5 doi: 10.1200/JCO.21.01881. PMID: 34985925
Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
Ganti AKP, Loo BW, Bassetti M, Blakely C, Chiang A, D'Amico TA, D'Avella C, Dowlati A, Downey RJ, Edelman M, Florsheim C, Gold KA, Goldman JW, Grecula JC, Hann C, Iams W, Iyengar P, Kelly K, Khalil M, Koczywas M, Merritt RE, Mohindra N, Molina J, Moran C, Pokharel S, Puri S, Qin A, Rusthoven C, Sands J, Santana-Davila R, Shafique M, Waqar SN, Gregory KM, Hughes M
J Natl Compr Canc Netw 2021 Dec;19(12):1441-1464. doi: 10.6004/jnccn.2021.0058. PMID: 34902832Free PMC Article

Recent clinical studies

Etiology

Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study.
Morgensztern D, Besse B, Greillier L, Santana-Davila R, Ready N, Hann CL, Glisson BS, Farago AF, Dowlati A, Rudin CM, Le Moulec S, Lally S, Yalamanchili S, Wolf J, Govindan R, Carbone DP
Clin Cancer Res 2019 Dec 1;25(23):6958-6966. Epub 2019 Sep 10 doi: 10.1158/1078-0432.CCR-19-1133. PMID: 31506387Free PMC Article
Role of Immune Checkpoint Inhibitors in Small Cell Lung Cancer.
Cooper MR, Alrajhi AM, Durand CR
Am J Ther 2018 May/Jun;25(3):e349-e356. doi: 10.1097/MJT.0000000000000686. PMID: 29722737
Consolidative thoracic radiotherapy for extensive stage small cell lung cancer.
Zhang X, Yu J, Zhu H, Meng X, Li M, Jiang L, Ding X, Sun X
Oncotarget 2017 Mar 28;8(13):22251-22261. doi: 10.18632/oncotarget.14759. PMID: 28118612Free PMC Article
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.
Antonia SJ, López-Martin JA, Bendell J, Ott PA, Taylor M, Eder JP, Jäger D, Pietanza MC, Le DT, de Braud F, Morse MA, Ascierto PA, Horn L, Amin A, Pillai RN, Evans J, Chau I, Bono P, Atmaca A, Sharma P, Harbison CT, Lin CS, Christensen O, Calvo E
Lancet Oncol 2016 Jul;17(7):883-895. Epub 2016 Jun 4 doi: 10.1016/S1470-2045(16)30098-5. PMID: 27269741
Lung cancer.
Frödin JE
Acta Oncol 1996;35 Suppl 7:46-53. doi: 10.3109/02841869609101662. PMID: 9154094

Diagnosis

Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
Ganti AKP, Loo BW, Bassetti M, Blakely C, Chiang A, D'Amico TA, D'Avella C, Dowlati A, Downey RJ, Edelman M, Florsheim C, Gold KA, Goldman JW, Grecula JC, Hann C, Iams W, Iyengar P, Kelly K, Khalil M, Koczywas M, Merritt RE, Mohindra N, Molina J, Moran C, Pokharel S, Puri S, Qin A, Rusthoven C, Sands J, Santana-Davila R, Shafique M, Waqar SN, Gregory KM, Hughes M
J Natl Compr Canc Netw 2021 Dec;19(12):1441-1464. doi: 10.6004/jnccn.2021.0058. PMID: 34902832Free PMC Article
DLL3: an emerging target in small cell lung cancer.
Owen DH, Giffin MJ, Bailis JM, Smit MD, Carbone DP, He K
J Hematol Oncol 2019 Jun 18;12(1):61. doi: 10.1186/s13045-019-0745-2. PMID: 31215500Free PMC Article
Consolidative thoracic radiotherapy for extensive stage small cell lung cancer.
Zhang X, Yu J, Zhu H, Meng X, Li M, Jiang L, Ding X, Sun X
Oncotarget 2017 Mar 28;8(13):22251-22261. doi: 10.18632/oncotarget.14759. PMID: 28118612Free PMC Article
A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo.
Saunders LR, Bankovich AJ, Anderson WC, Aujay MA, Bheddah S, Black K, Desai R, Escarpe PA, Hampl J, Laysang A, Liu D, Lopez-Molina J, Milton M, Park A, Pysz MA, Shao H, Slingerland B, Torgov M, Williams SA, Foord O, Howard P, Jassem J, Badzio A, Czapiewski P, Harpole DH, Dowlati A, Massion PP, Travis WD, Pietanza MC, Poirier JT, Rudin CM, Stull RA, Dylla SJ
Sci Transl Med 2015 Aug 26;7(302):302ra136. doi: 10.1126/scitranslmed.aac9459. PMID: 26311731Free PMC Article
Small-cell lung cancer.
Jackman DM, Johnson BE
Lancet 2005 Oct 15-21;366(9494):1385-96. doi: 10.1016/S0140-6736(05)67569-1. PMID: 16226617

Therapy

Emerging Strategies for the Treatment of Small Cell Lung Cancer: A Review.
Petty WJ, Paz-Ares L
JAMA Oncol 2023 Mar 1;9(3):419-429. doi: 10.1001/jamaoncol.2022.5631. PMID: 36520421
Extensive-Stage Small-Cell Lung Cancer: First-Line and Second-Line Treatment Options.
Zugazagoitia J, Paz-Ares L
J Clin Oncol 2022 Feb 20;40(6):671-680. Epub 2022 Jan 5 doi: 10.1200/JCO.21.01881. PMID: 34985925
DLL3: an emerging target in small cell lung cancer.
Owen DH, Giffin MJ, Bailis JM, Smit MD, Carbone DP, He K
J Hematol Oncol 2019 Jun 18;12(1):61. doi: 10.1186/s13045-019-0745-2. PMID: 31215500Free PMC Article
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.
Antonia SJ, López-Martin JA, Bendell J, Ott PA, Taylor M, Eder JP, Jäger D, Pietanza MC, Le DT, de Braud F, Morse MA, Ascierto PA, Horn L, Amin A, Pillai RN, Evans J, Chau I, Bono P, Atmaca A, Sharma P, Harbison CT, Lin CS, Christensen O, Calvo E
Lancet Oncol 2016 Jul;17(7):883-895. Epub 2016 Jun 4 doi: 10.1016/S1470-2045(16)30098-5. PMID: 27269741
A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo.
Saunders LR, Bankovich AJ, Anderson WC, Aujay MA, Bheddah S, Black K, Desai R, Escarpe PA, Hampl J, Laysang A, Liu D, Lopez-Molina J, Milton M, Park A, Pysz MA, Shao H, Slingerland B, Torgov M, Williams SA, Foord O, Howard P, Jassem J, Badzio A, Czapiewski P, Harpole DH, Dowlati A, Massion PP, Travis WD, Pietanza MC, Poirier JT, Rudin CM, Stull RA, Dylla SJ
Sci Transl Med 2015 Aug 26;7(302):302ra136. doi: 10.1126/scitranslmed.aac9459. PMID: 26311731Free PMC Article

Prognosis

Emerging Strategies for the Treatment of Small Cell Lung Cancer: A Review.
Petty WJ, Paz-Ares L
JAMA Oncol 2023 Mar 1;9(3):419-429. doi: 10.1001/jamaoncol.2022.5631. PMID: 36520421
Ferroptosis, necroptosis, and pyroptosis in the tumor microenvironment: Perspectives for immunotherapy of SCLC.
Niu X, Chen L, Li Y, Hu Z, He F
Semin Cancer Biol 2022 Nov;86(Pt 3):273-285. Epub 2022 Mar 12 doi: 10.1016/j.semcancer.2022.03.009. PMID: 35288298
Immunotherapy in Extensive-Stage Small Cell Lung Cancer.
El Sayed R, Blais N
Curr Oncol 2021 Oct 12;28(5):4093-4108. doi: 10.3390/curroncol28050347. PMID: 34677265Free PMC Article
Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study.
Morgensztern D, Besse B, Greillier L, Santana-Davila R, Ready N, Hann CL, Glisson BS, Farago AF, Dowlati A, Rudin CM, Le Moulec S, Lally S, Yalamanchili S, Wolf J, Govindan R, Carbone DP
Clin Cancer Res 2019 Dec 1;25(23):6958-6966. Epub 2019 Sep 10 doi: 10.1158/1078-0432.CCR-19-1133. PMID: 31506387Free PMC Article
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.
Antonia SJ, López-Martin JA, Bendell J, Ott PA, Taylor M, Eder JP, Jäger D, Pietanza MC, Le DT, de Braud F, Morse MA, Ascierto PA, Horn L, Amin A, Pillai RN, Evans J, Chau I, Bono P, Atmaca A, Sharma P, Harbison CT, Lin CS, Christensen O, Calvo E
Lancet Oncol 2016 Jul;17(7):883-895. Epub 2016 Jun 4 doi: 10.1016/S1470-2045(16)30098-5. PMID: 27269741

Clinical prediction guides

Emerging Strategies for the Treatment of Small Cell Lung Cancer: A Review.
Petty WJ, Paz-Ares L
JAMA Oncol 2023 Mar 1;9(3):419-429. doi: 10.1001/jamaoncol.2022.5631. PMID: 36520421
Extensive-Stage Small-Cell Lung Cancer: First-Line and Second-Line Treatment Options.
Zugazagoitia J, Paz-Ares L
J Clin Oncol 2022 Feb 20;40(6):671-680. Epub 2022 Jan 5 doi: 10.1200/JCO.21.01881. PMID: 34985925
Clinical characteristics and prognostic model for extensive-stage small cell lung cancer: A retrospective study over an 8-year period.
Ni J, Zhang X, Wang H, Si X, Xu Y, Zhao J, Chen M, Zhang L, Wang M
Thorac Cancer 2022 Feb;13(4):539-548. Epub 2021 Dec 30 doi: 10.1111/1759-7714.14289. PMID: 34970848Free PMC Article
Immunotherapy era in the treatment of small cell lung cancer.
Araz M, Karakurt Eryilmaz M
Med Oncol 2021 Jun 22;38(7):86. doi: 10.1007/s12032-021-01535-5. PMID: 34156575
A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo.
Saunders LR, Bankovich AJ, Anderson WC, Aujay MA, Bheddah S, Black K, Desai R, Escarpe PA, Hampl J, Laysang A, Liu D, Lopez-Molina J, Milton M, Park A, Pysz MA, Shao H, Slingerland B, Torgov M, Williams SA, Foord O, Howard P, Jassem J, Badzio A, Czapiewski P, Harpole DH, Dowlati A, Massion PP, Travis WD, Pietanza MC, Poirier JT, Rudin CM, Stull RA, Dylla SJ
Sci Transl Med 2015 Aug 26;7(302):302ra136. doi: 10.1126/scitranslmed.aac9459. PMID: 26311731Free PMC Article

Recent systematic reviews

Prognostic Factors of IIIAN2 Non-Small-Cell Lung Cancer after Complete Resection: A Systemic Review and Meta-analysis.
Wang Y, Wan Y, Qian Y
Comput Math Methods Med 2021;2021:1068090. Epub 2021 Dec 13 doi: 10.1155/2021/1068090. PMID: 34938347Free PMC Article
Initial management of small-cell lung cancer (limited- and extensive-stage) and the role of thoracic radiotherapy and first-line chemotherapy: a systematic review.
Sun A, Durocher-Allen LD, Ellis PM, Ung YC, Goffin JR, Ramchandar K, Darling G
Curr Oncol 2019 Jun;26(3):e372-e384. Epub 2019 Jun 1 doi: 10.3747/co.26.4481. PMID: 31285682Free PMC Article
Nodal recurrence after stereotactic body radiotherapy for early stage non-small cell lung cancer: Incidence and proposed risk factors.
Wink KCJ, van Baardwijk A, Troost EGC, De Ruysscher D
Cancer Treat Rev 2017 May;56:8-15. Epub 2017 Apr 12 doi: 10.1016/j.ctrv.2017.04.001. PMID: 28437679
Survival benefits from follow-up of patients with lung cancer: a systematic review and meta-analysis.
Calman L, Beaver K, Hind D, Lorigan P, Roberts C, Lloyd-Jones M
J Thorac Oncol 2011 Dec;6(12):1993-2004. doi: 10.1097/JTO.0b013e31822b01a1. PMID: 21892108
Evidence for management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition).
Samson DJ, Seidenfeld J, Simon GR, Turrisi AT 3rd, Bonnell C, Ziegler KM, Aronson N; American College of Chest Physicians
Chest 2007 Sep;132(3 Suppl):314S-323S. doi: 10.1378/chest.07-1384. PMID: 17873177

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...